What does this research mean for the field?

Delays in treatment initiation and lower utilization of Oncotype DX testing among Black patients contribute to worse breast cancer outcomes compared to White patients. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

This research examines the impact of treatment delays and disparities in testing on outcomes for node-positive ER+/HER2- breast cancer patients, focusing on racial differences.

February 19, 2026Clinical Cancer Research

Abstract PS4-11-16: Treatment Delays and Testing Disparities May Contribute to Racial Differences in Node-Positive ER+/HER2- Breast Cancer Outcomes

View Full Paper

Ask AI

Bookmark

Authors

LCLesley CoeAlbert Einstein College of Medicine MWMarilyn WoodAlbert Einstein College of Medicine SJS. JaoMontefiore Medical Center

Discussion

Member takes

Implication

This comparative analysis reveals treatment delays and lower Oncotype DX testing in Black patients affect outcomes in breast cancer, suggesting urgent attention.

Key Points

This research examines the impact of treatment delays and disparities in testing on outcomes for node-positive ER+/HER2- breast cancer patients, focusing on racial differences.
Conducted a retrospective chart review of patients from a Bronx institution (2018-2021) with node-positive ER+/HER2- breast cancer.
Identified a comparable cohort from the National Cancer Database (NCDB) for comparative analysis.
Compared treatment delays, Oncotype DX testing rates, and income levels between Black and White patients.
Black patients received Oncotype DX testing at lower rates (6.9%) compared to White patients (8.9%).
Delays from diagnosis to chemotherapy were longer for Black patients (43 days) than for White patients (38 days).
Black patients were significantly more likely to fall into the lowest income quartile and experienced longer treatment delays compared to higher-income patients.

Cite This Study

Coe et al. (2026) studied this question.

synapsesocial.com/papers/6996a8b5ecb39a600b3efaec https://doi.org/10.1158/1557-3265.sabcs25-ps4-11-16

View Full Paper

Ask AI

Bookmark

Implication

This comparative analysis reveals treatment delays and lower Oncotype DX testing in Black patients affect outcomes in breast cancer, suggesting urgent attention.

Abstract PS4-11-16: Treatment Delays and Testing Disparities May Contribute to Racial Differences in Node-Positive ER+/HER2- Breast Cancer Outcomes

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS4-11-16: Treatment Delays and Testing Disparities May Contribute to Racial Differences in Node-Positive ER+/HER2- Breast Cancer Outcomes

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider